TCIM
DNLI icon

TIAA CREF Investment Management’s Denali Therapeutics DNLI Stock Holding History

TIAA CREF Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.56M Sell
67,142
-2,914
-4% -$61K ﹤0.01% 2121
2018
Q4 		$1.45M Sell
70,056
-2,645
-4% -$48K ﹤0.01% 2135
2018
Q3 		$1.58M Buy
72,701
+36,599
+101% +$605K ﹤0.01% 2238
2018
Q2 		$551K Buy
36,102
+10,548
+41% +$199K ﹤0.01% 2747
2018
Q1 		$503K Buy
+25,554
New +$525K ﹤0.01% 2732

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

TIAA CREF Investment Management's DNLI Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Denali Therapeutics (DNLI) stake by 4.2% in Q1 2019, selling an estimated $61K and leaving 67,142 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

TIAA CREF Investment Management first reported a position in DNLI in Q1 2018 and has held it in 5 quarters since. The position peaked at $1.58M in Q3 2018. 114 funds tracked by Wall St. Rank hold DNLI as of Q1 2019.

  • TIAA CREF Investment Management held 67,142 shares of Denali Therapeutics worth $1.56M as of Q1 2019.
  • TIAA CREF Investment Management sold 2,914 Denali Therapeutics shares in Q1 2019, an estimated $61K.
  • Denali Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2121 holding.
  • TIAA CREF Investment Management first reported a position in Denali Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • TIAA CREF Investment Management's Denali Therapeutics position peaked at $1.58M in Q3 2018.
  • 114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.